OKYO Pharma Limited (OKYO)

NASDAQ: OKYO · IEX Real-Time Price · USD
1.230
0.00 (0.00%)
At close: Jun 24, 2024, 10:31 AM
1.210
-0.020 (-1.63%)
After-hours: Jun 24, 2024, 4:12 PM EDT
0.00%
Market Cap 40.22M
Revenue (ttm) n/a
Net Income (ttm) -13.27M
Shares Out 33.24M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,184
Open 1.230
Previous Close 1.230
Day's Range 1.210 - 1.230
52-Week Range 0.920 - 3.070
Beta -3.26
Analysts Strong Buy
Price Target 7.00 (+469.11%)
Earnings Date Aug 13, 2024

About OKYO

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, th... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 17, 2022
Employees 8
Stock Exchange NASDAQ
Ticker Symbol OKYO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for OKYO stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(469.11% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla...

7 weeks ago - GlobeNewsWire

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla...

2 months ago - GlobeNewsWire

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla...

2 months ago - GlobeNewsWire

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief

3 months ago - GlobeNewsWire

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

- Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDA...

3 months ago - GlobeNewsWire

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla...

3 months ago - GlobeNewsWire

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

LONDON and NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam...

4 months ago - GlobeNewsWire

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory ...

6 months ago - GlobeNewsWire

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

LONDON and NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory ...

9 months ago - GlobeNewsWire

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to ...

10 months ago - GlobeNewsWire

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to ...

10 months ago - GlobeNewsWire

OKYO Pharma Limited Announces Withdrawal of Public Offering

LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to ...

10 months ago - GlobeNewsWire

OKYO Pharma Announces Public Offering of Ordinary Shares

LONDON and NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to ...

10 months ago - GlobeNewsWire

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

LONDON and NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory...

10 months ago - GlobeNewsWire

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

LONDON and NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat DED to address the si...

10 months ago - GlobeNewsWire

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

LONDON and NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED...

11 months ago - GlobeNewsWire

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to t...

11 months ago - GlobeNewsWire

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry ey...

11 months ago - GlobeNewsWire

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED...

11 months ago - GlobeNewsWire

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

LONDON and NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED)...

11 months ago - GlobeNewsWire

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease

LONDON and NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED)...

1 year ago - GlobeNewsWire

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

BALTIMORE, MD / ACCESSWIRE / May 9, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new rese...

1 year ago - Accesswire

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to ...

1 year ago - GlobeNewsWire

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

LONDON and NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye dis...

1 year ago - GlobeNewsWire

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 t...

1 year ago - GlobeNewsWire